Two other large series have studied the efficacy of HD IL-2 in patients with melanoma and renal cell carcinoma (RCC): Providence Cancer Center (314 melanoma patients) [25] and a more recent PROCLAIMSM registry (170 melanoma patients) study [26]. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.